ILB-3101

N/A

Report date: 2024/12/17 13:40:46

Base Information

Drug NameILB-3101
Drug Alias NameILB-3101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Eribulin payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CD276Tubulin inhibitors
TargetsCD276 antigenTubulin
Therapy Area/IndicationsSolid tumoursLeukemia, Myeloid, AcuteNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesInnolake Biopharm (Hangzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEllipses Pharma LtdInnolake Biopharm (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLeukemia, Myeloid, Acute
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A